HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients

JACC50-12.pdf290.24 kBPDF見る/開く

タイトル: Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients
著者: Naya, Masanao 著作を一覧する
Tsukamoto, Takahiro 著作を一覧する
Morita, Koichi 著作を一覧する
Katoh, Chietsugu 著作を一覧する
Furumoto, Tomoo 著作を一覧する
Fujii, Satoshi 著作を一覧する
Tamaki, Nagara 著作を一覧する
Tsutsui, Hiroyuki 著作を一覧する
キーワード: coronary endothelial function
positron emission tomography
発行日: 2007年 9月18日
出版者: Elsevier Inc.
誌名: Journal of the American College of Cardiology
巻: 50
号: 12
開始ページ: 1144
終了ページ: 1149
出版社 DOI: 10.1016/j.jacc.2007.06.013
抄録: Objectives: We aimed to compare the effects of angiotensin II receptor blocker (ARB) olmesartan versus calcium channel blocker (CCB) amlodipine on coronary endothelial dysfunction in patients with hypertension. Background: ARB is thought to have greater beneficial effects on coronary vasomotion via directly blocking action of angiotensin II than CCB. Methods: Twenty-sex patients with untreated essential hypertension were prospectively assigned to the treatment with either olmesartan (27.7±12.4 mg per day, n=13) or amlodipine (5.6±1.5 mg per day, n=13) for 12 weeks. Changes of corrected myocardial blood flow (ΔMBF) and coronary vascular resistance (ΔCVR) from rest to cold pressor were measured by using 15O-water and positron emission tomography before and after treatment. Blood biomarkers including lipids, glucose, insulin, hs-CRP, interleukin-6, tumor necrosis factor-α, and superoxide dismutase (SOD) were also measured. Results: Olmesartan and amlodipine reduced blood pressure (BP) to the same extent (−28.7±16.2 vs. −26.7±10.8 mmHg). In olmesartan group, ΔMBF tended to be greater (−0.15±0.19 vs. 0.03±0.17 ml/g/min, P=0.09 by 2-way ANOVA) and ΔCVR was significantly decreased (7.9±23.5 vs. −16.6±18.0 mmHg/[ml/g/min], P<0.05) after treatment whereas they did not change in amlodipine group (ΔMBF: −0.15±0.12 vs. −0.12±0.20 ml/g/min; ΔCVR: 6.5±18.2 vs. 4.8±23.4 mmHg/[ml/g/min]). Serum SOD activity tended to increase (4.74±4.77 vs. 5.57±4.74 U/ml, P=0.07 by 2-way ANOVA) only in olmesartan group. Conclusions: Olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation in hypertensive patients independently of BP lowering. These beneficial effects on coronary vasomotion might be via an antioxidant property of ARBs.
資料タイプ: article (author version)
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 納谷 昌直


本サイトに関するご意見・お問い合わせは repo at へお願いします。 - 北海道大学